Allergan (Abbvie) is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
With the increased number of therapeutic rAAV candidates reaching the clinical trial pipeline, there is demand for innovative technologies to improve process development and facilitate manufacturing scale-up for future commercialization. To this end, Polyplus-transfection has worked hand-in-hand with viral vector manufacturers to develop a transfection reagent specifically for large scale manufacturing in suspension cell systems: FectoVIR®-AAV. FectoVIR®-AAV aims to improve rAAV manufacturing processes by boosting productivity, bringing flexibility and facilitating scalability. Here, we share preliminary data from Allergan Biologics’ recent evaluation of FectoVIR®-AAV against their current AAV production platform. Analysis of physical titers revealed a 3-fold increase in both viral particles (VP) and viral genome (VG) per ml of cell culture when using FectoVIR®-AAV transfection reagent compared to PEIpro®.